on ABIVAX (EPA:ABVX)
Abivax presents obefazimod at UEG Week 2026
At United European Gastroenterology (UEG) Week 2026, Abivax, a biotechnology company, will present key data on obefazimod, its lead drug candidate for moderate to severe active ulcerative colitis. The presentations will be based on results from the Phase 2 and 3 ABTECT clinical trials, as well as preclinical work on the antifibrotic and antitumor properties of obefazimod.
Marc de Garidel, CEO of Abivax, emphasizes the importance of this data for better understanding the potential of obefazimod in the treatment of chronic inflammatory bowel diseases. The company aims to address unmet medical needs. This initiative demonstrates Abivax's commitment to promoting innovative therapeutic solutions in the field of gastroenterology.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news